More money should be spent on researching the causes of complex diseases that require personalised medical treatment, according to Germany’s science academies.
The academies say that more research is needed to find biomarkers for personalised medicine, understand disease and treatment progress, and create awareness of the ethical consequences of personalised medical treatments. Such consequences include the impact of treatments on data gathering and protection, and on clinical trials.
In a position paper issued this week, the Leopoldina, Germany’s academy of sciences, and Acatech, the academy for technical sciences, analyse the progress of personalised medicine in Europe. They say that such medicines hold great potential, but that more money must be spent on research into their wider impact on medicine and human wellbeing.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.